Henryk Barthel

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

PET imaging utilization and trends in Germany: a comprehensive survey

Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease

EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease

SNMMI Procedure Standard/EANM Practice Guideline for Brain [¹⁸F]FDG PET Imaging, Version 2.0

Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies

Added value of FDG-PET for detection of progressive supranuclear palsy

What Is Theranostics?

Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies

Theranostics in Neurooncology: Heading Toward New Horizons

Association of Neurofilament Light Chain, [ ¹⁸ F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid–Negative CBS

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Tau deposition patterns are associated with functional connectivity in primary tauopathies

International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease

2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee

Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Cortical [<scp>¹⁸F</scp>]<scp>PI</scp>‐2620 Binding Differentiates Corticobasal Syndrome Subtypes

Binding characteristics of [ ¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET

Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy

Toward a Universal Readout for¹⁸F-Labeled Amyloid Tracers: The CAPTAINs Study

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

<scp>JuSpace</scp>: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps

EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

The Future of Nuclear Medicine, Molecular Imaging, and Theranostics

Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury

COVID-19 and the brain: impact on nuclear medicine in neurology